Antibody and use thereof
AssigneeTakeda Pharmaceutical Company Limited
InventorsHirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
Life of this patent
Estimating the term…
Abstract
The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.
Claims13
A monoclonal antibody, P2L-1Ca, that specifically binds with a peptide comprising the amino acid sequence SEQ ID NO:
- 7 produced by a hybridoma deposited with the Ministry of International Trade and Industry National Institute of Bioscience and Human Technology as Accession No. NIBH-6299.
An isolated hybridoma cell deposited with the Ministry of International Trade and Industry National Institute of Bioscience and Human Technology as Accession No. NIBH-6299.
Dependencies are inferred from the claim text.